Rahul Banerjee, MD, FACP
LightNews LightNews
banner
rahulbanerjeemd.bsky.social
Rahul Banerjee, MD, FACP
@rahulbanerjeemd.bsky.social
1.4K followers 60 following 34 posts
Assistant Professor at Fred Hutch Cancer Center (Seattle, WA, USA) specializing in multiple myeloma #MMsm and CAR-T therapy.

My research focus: improving the patient experience in myeloma.

COI: https://coi.asco.org/share/VU2-FHC3/Rahul%20Banerjee
Posts Replies Media Videos
Reposted by Rahul Banerjee, MD, FACP
i3health.bsky.social
What can #TheWhiteLotus teach us about cancer care? 🏝️ Dr. Rahul Banerjee, explores “time toxicity” and why every patient’s journey is unique. How can we better tailor care? Read more: ow.ly/lqjr50VM5zO #Oncology #PatientCare
What the Oncology Field Can Learn From The White Lotus
Editor in Chief Dr. Rahul Banerjee's April Letter from the Editor explains what the oncology field can learn from "The White Lotus."
ow.ly
May 7, 2025 at 6:35 PM
Reposted by Rahul Banerjee, MD, FACP
yleyfman.bsky.social
New study in Blood Advances led by Rahul Banerjee & Gurbakhash Kaur challenges the 8-week driving restriction for patients receiving CAR-T therapy for multiple myeloma (MM). Researchers analyzed 586 patients and found that only 1% experienced driving-relevant adverse events (drAEs) between Weeks 5-8
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg
ashpublications.org
March 17, 2025 at 11:49 PM
Reposted by Rahul Banerjee, MD, FACP
targetedonc.bsky.social
Rahul Banerjee, MD, (@rahulbanerjeemd.bsky.social) discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma. #mmsm | @uwmedicine.bsky.social @fredhutch.bsky.social

www.targetedonc.com/view/banerje...
January 17, 2025 at 5:56 PM
Reposted by Rahul Banerjee, MD, FACP
yleyfman.bsky.social
@rahulbanerjeemd.bsky.social @fredhutch.bsky.social @mountsinainyc.bsky.social @mountsinai.bsky.social

ashpublications.org/bloodadvance...
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg
ashpublications.org
March 17, 2025 at 11:49 PM
Reposted by Rahul Banerjee, MD, FACP
oncodaily.bsky.social
Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma - Rahul Banerjee
@rahulbanerjeemd.bsky.social

oncodaily.com/drugs/financ...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MM #MultipleMyeloma #Myeloma #Lenalidomide
Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma - OncoDaily
Rahul Banerjee: Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma / cancer, Financial Toxicity of Drugs, OncoDaily, Oncology
oncodaily.com
May 9, 2025 at 5:22 PM
Reposted by Rahul Banerjee, MD, FACP
oncodaily.bsky.social
Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma - Rahul Banerjee
@rahulbanerjeemd.bsky.social @cancertherapyadv.bsky.social

oncodaily.com/insight/rahu...

#Cancer #CancerResearch #HairLoss #Myeloma #BloodCancer #CancerTreatment #Oncology #OncoDaily
Rahul Banerjee: Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma - OncoDaily
Rahul Banerjee: Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma / cancer, Cancer Therapy Advisor, MM, multiple myeloma,
oncodaily.com
March 9, 2025 at 6:05 PM
rahulbanerjeemd.bsky.social
My takeaways from RedirecTT-1 (tal/tec dual bsAbs in myeloma #MMsm) for @fredhutch journal watch.

[Images but technically no memes in my talk 😉]

Efficacy & safety profiles are both striking! I can't help but wonder what earlier IVIG and bsAb de-escalation might have done.
January 17, 2025 at 3:30 AM
Reposted by Rahul Banerjee, MD, FACP
vjhemonc.bsky.social
At #ASH24, we caught up with Rakesh Popat to hear the interim results of the ProMMise trial evaluating belantamab + cyclophosphamide & dexamethasone in R/R #Myeloma.

Watch here:
👉https://buff.ly/3W3Cgy2

#MMSM #CTSM #TrialUpdate #MultipleMyeloma #HemeSky #HemeOnc
@ash-hematology.bsky.social
January 5, 2025 at 12:00 PM
Reposted by Rahul Banerjee, MD, FACP
bloodyminded.bsky.social
Very excited to have Prof Tracy King @mmkingt.bsky.social on for a look at the ins and outs of myeloma nursing! She makes a great friendalidomide to anyone navigating this area, wherever you get your podcasts #myeloma #hemesky #meded

www.bloodyminded.com.au/allepisodes/...
Episode 31 - Advanced Myeloma Nursing with A/Prof Tracy King — Bloody Minded
Thankfully, it's time for an actual expert to join us again on Bloody Minded! We are thrilled to be sitting down and chatting with A/Prof. Tracy King , Myeloma CNC from RPA Hospital in Sydney, Co-Fou...
www.bloodyminded.com.au
January 8, 2025 at 1:05 AM
Reposted by Rahul Banerjee, MD, FACP
vjhemonc.bsky.social
The PANGEA 2.0 model leverages trajectory data to improve the risk stratification of individuals with #SmolderingMyeloma.

Learn more in our recent interview with the lovely Irene Ghobrial:

👉https://buff.ly/49ZYSFl

#Myeloma #MMSM #ASH24 #Hematology #HemeSky #HemeOnc @ash-hematology.bsky.social
January 8, 2025 at 10:00 AM
Reposted by Rahul Banerjee, MD, FACP
remydulery.bsky.social
Happy to share our work published in Nature Medicine!

We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...
T cell malignancies after CAR T cell therapy in the DESCAR-T registry - Nature Medicine
This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell therapy in France between 2018 and 2024 shows th...
www.nature.com
January 8, 2025 at 2:23 PM
Reposted by Rahul Banerjee, MD, FACP
nejm.org
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY

Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
January 9, 2025 at 2:14 PM
Reposted by Rahul Banerjee, MD, FACP
onclive.bsky.social
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayocliniccancer.bsky.social #mmsm #oncology
www.onclive.com/view/subcuta...
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.
www.onclive.com
January 9, 2025 at 4:21 PM
Reposted by Rahul Banerjee, MD, FACP
medicine.stitches.today
Dexamethasone dose reductions during multiple myeloma treatment show no difference in survival outcomes, highlighting the need for further research.

by Banerjee R, Sexton R (...) Orlowski RZ et 11 al. in Blood #MedSky

📖 read the article:
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Key PointsDexamethasone dose reductions <40 to 60 mg weekly are common in multiple myeloma, even for patients enrolled on clinical trials.In our large a
ashpublications.org
January 11, 2025 at 6:34 AM
Reposted by Rahul Banerjee, MD, FACP
hannahrabrams.bsky.social
Two cool #ASH24 abstracts on reducing logistical toxicity for patients:

1. A via @rahulbanerjeemd.bsky.social et al: multi-method real world data to show <1% new-onset CRS/ICANS weeks 5-8-- let people drive! Key for getting to follow up appts after returning home.
Abstract Title: #3765 Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium Abstract Title: #445 Outpatient Vs Inpatient Hidac Consolidation for AML: The MSKCC Experience.
December 6, 2024 at 6:32 AM
Reposted by Rahul Banerjee, MD, FACP
dianekennedy.bsky.social
Care partners favorite - the “Down with Dex” doctor! @rahulbanerjeemd.bsky.social @ctoddkennedy.bsky.social
December 7, 2024 at 12:20 PM
Reposted by Rahul Banerjee, MD, FACP
fredhutch.org
Fred Hutch at #ASH24: Catch @rahulbanerjeemd.bsky.social present results of a phase 3 clinical trial of 500 patients demonstrating that 24-hour urine assessments do not add any value or improve prognosis. 👉 bit.ly/49jbaIo
December 7, 2024 at 5:11 PM
Reposted by Rahul Banerjee, MD, FACP
tanyawildes.bsky.social
Let’s throw out the jugs!
@rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24
December 7, 2024 at 5:59 PM
Reposted by Rahul Banerjee, MD, FACP
hemedoc.bsky.social
#ASH24 #leusm Heuser: Proposes a reasonable evolution for the meaning of the term MRD. @drchrishourigan.bsky.social @rahulbanerjeemd.bsky.social
December 7, 2024 at 6:13 PM
Reposted by Rahul Banerjee, MD, FACP
biostatgirl.bsky.social
Free multiple myeloma response criteria from the pee! Excellent #ASH24 presentation by @rahulbanerjeemd.bsky.social showing that removing 24-hr urine changes response for only 1.1% of 645 patients in the BMT CTN 0702 clinical trial.
December 7, 2024 at 6:20 PM
Reposted by Rahul Banerjee, MD, FACP
cancercommunicator.com
Can 24h urine be eliminated as part of IMWG response criteria in myeloma? Secondary analysis of STaMINA by @rahulbanerjeemd.bsky.social at #ASH24 showed that eliminating 24h urine resulted in changed response in 1% with no impact on PFS prediction at any response depth. #hemesky #oncsky #mmsm
December 7, 2024 at 6:45 PM
Reposted by Rahul Banerjee, MD, FACP
vjhemonc.bsky.social
What a blast #ASH24 has been!🎥🗞️🩸🇺🇸

Thank you to everyone who has been stopping by our booth 🧡

& BIG thank you to everyone who spoke with us🎙️

Stay tuned as we continue to share our exclusive coverage 👀 👉 vjhemonc.com/event/ash-2024

@ash-hematology.bsky.social @rahulbanerjeemd.bsky.social

#HemOnc
December 9, 2024 at 7:51 PM
rahulbanerjeemd.bsky.social
Also out in @BloodAdvances during #ASH24 by rising 🌟 @nadineabdal and @MayoMyeloma!

PROs strongly correlate with OS in #MMsm. In MVA, fatigue as prognostic for OS as FISH and ASCT 😳

Some confounders (anemia, frailty) but worth studying interventions!

ashpublications.org/bloodadvance...
December 13, 2024 at 6:51 PM
rahulbanerjeemd.bsky.social
Out in @bloodjournal during #ASH24 - cool work by @freemanlciaraMD @DrFredLocke et al looking at #MMsm CAR-T in myeloma:

MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.

ashpublications.org/blood/articl...
December 13, 2024 at 6:49 PM
Reposted by Rahul Banerjee, MD, FACP
justjanis1.bsky.social
It's really incredible how far things have come.
November 30, 2024 at 9:22 AM